The U.S. Food and Drug Administration (FDA ... is a rapid-acting human insulin analog designed to reduce spikes in blood ...

WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) recently approved Merilog (insulin-aspart-szjj) as the first rapid-acting insulin biosimilar to Novolog (insulin aspart).

Feb. 20, 2025 -- The FDA has approved a new fast-acting insulin biosimilar to help manage blood sugar in people with diabetes, including children and adults. The product, called Merilog ...

Additionally, the number of cases has been rising at a much faster rate in low- and middle-income ... in the press release. 1. FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment ...

The Food and Drug Administration (FDA) has approved Merilog (insulin-aspart ... the prefilled pen dials in 1-unit increments. The rapid-acting insulin should be administered subcutaneously within ...

Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin biosimilar product approved by the FDA. As a rapid-acting insulin, Merilog helps to lower mealtime blood sugar ...

FDA Approves First Rapid-Acting Insulin Biosimilar for Patients With Diabetes By Stephanie Brown HealthDay Reporter WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- The U.S. Food and Drug ...

Merilog is a rapid-acting human insulin analog and the first rapid-acting insulin biosimilar product approved by the FDA. Administering Merilog subcutaneously five to 10 minutes before mealtime ...